Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition

PURPOSE: Chk1 inhibitors, such as AZD7762 are in clinical development in combination with cytotoxic agents for the treatment of solid tumors, including pancreatic cancers. To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic bio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Parsels, Leslie A., Qian, Yushen, Tanska, Daria M., Gross, Marisa, Zhao, Lili, Hassan, Maria C., Arumugarajah, Sankari, Parsels, Joshua D., Hylander-Gans, Linda, Simeone, Diane M., Morosini, Deborah, Brown, Jeffrey L., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S., Morgan, Meredith A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107893/
https://ncbi.nlm.nih.gov/pubmed/21482692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-3082
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak